MoneyWorks4Me

Sanjivani Paranteral - Quaterly Results

08 Aug 2022 Evaluate
A fair growth of 22.70% in the revenue at Rs. 99.17 millions was reported in the June 2022 quarter as compared to Rs. 80.82 millions during year-ago period.The company almost doubled its revenue to Rs. 17.97 millions  from Rs. 6.28 millions in the quarter ended June 2022.Operating profit for the quarter ended June 2022 rose to 22.74 millions as compared to 8.35 millions of corresponding quarter ended June 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 99.17 80.82 22.70 99.17 80.82 22.70 306.13 251.00 21.96
Other Income 1.17 0.72 62.50 1.17 0.72 62.50 2.43 2.58 -5.81
PBIDT 22.74 8.35 172.34 22.74 8.35 172.34 59.69 23.99 148.81
Interest 0.74 0.31 138.71 0.74 0.31 138.71 2.13 1.26 69.05
PBDT 22.00 8.04 173.63 22.00 8.04 173.63 57.56 22.73 153.23
Depreciation 2.17 1.76 23.30 2.17 1.76 23.30 8.77 8.60 1.98
PBT 19.83 6.28 215.76 19.83 6.28 215.76 48.79 14.13 245.29
TAX 1.86 0.00 0.00 1.86 0.00 0.00 0.32 -0.07 -557.14
Deferred Tax -0.64 0.00 0.00 -0.64 0.00 0.00 0.32 -0.07 -557.14
PAT 17.97 6.28 186.15 17.97 6.28 186.15 48.47 14.20 241.34
Equity 99.98 84.98 17.65 99.98 84.98 17.65 99.98 84.98 17.65
PBIDTM(%) 22.93 10.33 121.94 22.93 10.33 121.94 19.50 9.56 104.00
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..